1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Sedana Medical AB (publ)

Sedana Medical AB (publ)

SEDANA.ST
Sedana Medical AB (publ)SE flagStockholm Stock Exchange
8.97
SEK
+0.11
- -
891.05MMarket Cap
Sedana Medical AB (publ)
SEDANA.ST
(Stockholm Stock Exchange)

Recent

price

8.97

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.41
0.47
0.59
0.76
0.86
1.55
1.72
1.24
1.55
1.8
2.02
1.97
Revenue per Share
-0.02
0.02
-0.06
-0.09
-0.2
-0.3
-0.62
-0.74
-0.6
-0.11
-0.6
-0.51
Basic EPS, GAAP
- -
-0.08
-0.37
-0.46
-0.73
-1.01
-1.63
-2.55
-2.08
-1.88
-0.76
-1.32
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
0.03
-0.26
-0.43
-0.69
-1.31
-1.96
-2.56
-2.67
-3.26
-3.04
Book Value per Share
-0.01
-0.05
1.32
2.17
5.61
4.17
8.96
6.4
4.27
2.29
1.31
1.67
Tangible Book Value per Share
68
68
68
77
84
92
93
99
99
99
99
99
Basic Weighted Avg Shares
28
32
40
58
72
142
159
123
154
179
200
196
Sales/Revenue/Turnover
-4.93
0.85
-8.95
-14.76
-23.28
-15.19
-38.45
-84.59
-43.25
-28.41
-16.26
-20.55
Operating Margin (%)
- -
- -
3
6
7
14
13
24
25
23
22
23
Depreciation Expense
-1
1
-4
-7
-16
-27
-58
-74
-60
-11
-59
-51
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.23
Effective Tax Rate (%)
-4.29
4
-9.59
-11.86
-22.86
-19.14
-36.42
-59.83
-38.74
-5.97
-29.59
-25.93
Profit Margin (%)
6
2
84
159
461
371
819
625
417
226
122
169
Working Capital
5
5
- -
1
1
5
5
4
1
3
2
2
LT Debt
- -
1
116
218
569
551
1,101
1,029
970
958
901
920
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4.19
Return on Capital (%)
- -
592.44
-402.82
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
3
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
3
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
99
99
99
Market Capitalization
1,895
788
1,099

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
278
247
216
Cash, Cash Equivalents & STI
194
165
131
Accounts Receivable, Net
27
26
28
Inventories
46
40
40
Total Current Liabilities
52
51
47
Payables & Accruals
- -
- -
- -
ST Debt
3
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
963.25%
16.07%
-6%
Free Cash Flow
- -
8.65%
-59.74%
Net Income, GAAP
16.77%
98.89%
455.03%
Sales/Revenue/Turnover
24.78%
8.57%
12.01%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
49
41
40
49
179
2025
57
50
52
- -
200
2026
53
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
-0.17
-0.23
0.09
-0.11
2025
-0.24
-0.13
-0.1
- -
-0.6
2026
-0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Tellgen Corporation (300642.SZ)
EKF Diagnostics Holdings plc (EKF.L)
Southwestern Medical Solutions, Inc. (SWNM)
CellaVision AB (publ) (CLVSF)
LexaGene Holdings Inc. (LXXGF)
Ningbo David Medical Device Co., Ltd. (300314.SZ)
Business
Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation for mechanically ventilated patients in intensive care; it develops, manufactures, markets and sells medical devices and pharmaceuticals including the Sedaconda ACD (formerly AnaConDa), a disposable device for administering volatile anesthetics with high reflection efficiency, bacterial/viral filtration and heat/moisture exchange; Sedaconda ACD-L and ACD-S variants for longer and shorter durations; Sedaconda Syringe for precise agent delivery; Sedaconda (isoflurane) for adult sedation; scavenging products such as FlurAbsorb and FlurAbsorb-S carbon filters, Scavenging Tubes and mounts; gas monitoring equipment like the AMG-06 Gas Monitor for CO2 and anesthetic concentrations; and accessories including Dryline II Water Traps and gas sampling lines. The company conducts clinical development to expand applications, including pediatric use and US market entry targeting FDA approval and 2027 launch. Sedana Medical maintains direct sales in Benelux, France, Germany, Great Britain, Nordics and Spain, with distributors across other parts of Europe, Asia, Australia, Canada and South/Central America; founded in 2005, it is headquartered in Danderyd, Stockholm, Sweden, and listed on Nasdaq Stockholm (SEDANA.ST). In 2025, the company completed the acquisition of its main supplier Innovatif Cekal for 34 MSEK to enhance supply chain control and reduce costs of goods sold, a transaction announced in July 2024 and financed from cash reserves, expected to improve operational cash flow from 2025 onward.